Amgen wades deeper into Asia with full control of an Astellas Japanese JV

On the heels of a $2.7 billion tie-up with BeiGene in China, Amgen is now on track to take full control of a Japanese joint venture with Astellas, as the Big Biotech bets more on the rapidly growing Asian market. The move comes on the heels of a $2.7 billion BeiGene tie-up and feeds into the company's goal of 25% growth in Asia.